Clinical Trial Update: Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance [Phase 2]

View source ↗

Summary

A Phase 2 trial from Korea University Guro Hospital is evaluating secondary cytoreductive surgery for relapsed ovarian cancer in patients who progressed on PARP…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Snippet

Sponsor: Korea University Guro Hospital | Conditions: Ovarian Cancer, Drug Related Neoplasm/Cancer | Phase 2 | Status: RECRUITING